Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis


Will Hemispherx Biopharma Make The Cut? (HEB)

By Mike Brown on 07/06/2009 – 6:00 am PDTLeave a Comment

It has been over a month since the FDA last informed Hemispherx Biopharma (AMEX:HEB) “it may require up to 1-2 additional weeks” to make its decision on HEB’s drug Ampligen, a treatment for Chronic Fatigue Syndrome. So now investors are in this state of “limbo” and no one knows when the FDA will make their decision.

According to a conference call, Dr. Carter stated Ampligen has a 80% chance of approval and possibly higher since the drug is classified as a NMW (New Molecular Entity) for which no other treatments exists. Only time will tell, until then we continue to wait.

If Ampligen is approved this will be the first and only FDA approved treatment for CFS with a estimated market of about 4 Million people.

Let us know what you think about HEB on the stock forums. You will notice stock market forums don’t have the usual pumpers, spammers, and trolls.

You can find information about Hemispherx Biopharma (AMEX:HEB) on the links below

Hemispherx Biopharma - HEB


  • No related articles found
  • Comments are closed.